Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.41 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3433280 | 0.96 | CYP2A6 (0.44) | SMN1; SMN2NPC1ALDH1A1EPHX2CYP2A6 | |
| SCHEMBL2134924 | 0.89 | NPC1 (0.41) | SMN1; SMN2NPC1ALDH1A1EPHX2 | |
| SCHEMBL3433076 | 0.86 | CYP2A6 (0.48) | CYP2A6POLQ | |
| SCHEMBL3434332 | 0.85 | CYP2A6 (0.46) | SMN1; SMN2NPC1CYP2A6HTT | |
| SCHEMBL2135477 | 0.85 | — | — | |
| SCHEMBL3434667 | 0.85 | CYP2A6 (0.42) | NPC1CYP2A6 | |
| SCHEMBL3434335 | 0.82 | CYP2A6 (0.44) | CYP2A6 | |
| SCHEMBL3430453 | 0.81 | MAPK1 (0.39) | MAP4K1 | |
| SCHEMBL3432677 | 0.80 | CYP2A6 (0.43) | CYP2A6 | |
| SCHEMBL3431752 | 0.80 | CYP2A6 (0.43) | CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | SMN1; SMN2 2886/4885NPC1 1917/4885ALDH1A1 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.